0.397
price down icon0.75%   -0.003
after-market After Hours: .40 0.003 +0.76%
loading
Nextcure Inc stock is traded at $0.397, with a volume of 129.40K. It is down -0.75% in the last 24 hours and down -45.54% over the past month.
See More
Previous Close:
$0.40
Open:
$0.388
24h Volume:
129.40K
Relative Volume:
1.10
Market Cap:
$11.12M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-0.19
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
-25.19%
1M Performance:
-45.54%
6M Performance:
-69.69%
1Y Performance:
-83.46%
1-Day Range:
Value
$0.375
$0.4049
1-Week Range:
Value
$0.3518
$0.5594
52-Week Range:
Value
$0.3518
$2.49

Nextcure Inc Stock (NXTC) Company Profile

Name
Name
Nextcure Inc
Name
Phone
240-399-4900
Name
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
Employee
0
Name
Twitter
@nextcureinc
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
NXTC's Discussions on Twitter

Compare NXTC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NXTC
Nextcure Inc
0.397 11.12M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-04-22 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-22 Initiated Ladenburg Thalmann Buy
Mar-05-21 Upgrade Truist Hold → Buy
Jan-15-21 Downgrade BofA Securities Neutral → Underperform
Jul-16-20 Upgrade The Benchmark Company Hold → Buy
Jul-13-20 Downgrade ROTH Capital Buy → Neutral
Jul-13-20 Downgrade SunTrust Buy → Hold
Jun-01-20 Downgrade BofA/Merrill Buy → Neutral
Jun-01-20 Downgrade The Benchmark Company Buy → Hold
May-26-20 Initiated JMP Securities Mkt Outperform
Mar-24-20 Initiated The Benchmark Company Buy
Mar-02-20 Initiated ROTH Capital Buy
Jan-13-20 Initiated SunTrust Buy
Dec-05-19 Initiated Needham Buy
Nov-26-19 Initiated BTIG Research Buy
Jul-09-19 Initiated BofA/Merrill Buy
Jun-03-19 Initiated Morgan Stanley Overweight
Jun-03-19 Initiated Piper Jaffray Overweight
View All

Nextcure Inc Stock (NXTC) Latest News

pulisher
02:24 AM

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

02:24 AM
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025
pulisher
Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

2 Net Current Asset Value Stocks to Consider - GuruFocus.com

Mar 10, 2025
pulisher
Mar 08, 2025

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

NextCure Reports 2024 Financials and Strategic Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com

Feb 27, 2025
pulisher
Feb 27, 2025

NextCure stock plunges to 52-week low, hits $0.69 - MSN

Feb 27, 2025
pulisher
Feb 12, 2025

NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 10, 2025

Ventia Strengthens Leadership with New Company Secretary Appointment - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance

Feb 10, 2025
pulisher
Feb 06, 2025

Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World

Feb 04, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈

Jan 12, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan

Jan 10, 2025
pulisher
Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia

Dec 25, 2024
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa

Dec 25, 2024
pulisher
Dec 17, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 16, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India

Dec 16, 2024
pulisher
Dec 12, 2024

The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World

Dec 12, 2024
pulisher
Dec 11, 2024

FDA clears IND for B7-H4-targeting ADC - BioWorld Online

Dec 11, 2024
pulisher
Dec 10, 2024

NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan

Dec 10, 2024
pulisher
Dec 07, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia

Dec 07, 2024
pulisher
Dec 06, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa

Dec 06, 2024

Nextcure Inc Stock (NXTC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):